Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.

Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncol. 2016 Apr; 17(4):496-508.

View in: PubMed

subject areas

Aged
Azacitidine
Disease-Free Survival
DNA Methylation
Drug Administration Schedule
Europe
Female
Glycine
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Myelodysplastic Syndromes
Risk
Sulfones
Treatment Outcome

authors with profiles

Lucy Godley